"Braeburn Pharmaceuticals and Camurus today announce top line results of a multipledose pivotal Phase  study assessing the blockade by CAM of subjective opioid effects of multiple randomized hydromorphone challenges in adults with opioid use disorder.   A key objective of medicationassisted treatment for opioid use disorder is to reduce or eliminate the use of illicit opioids. The results from the present Phase  study demonstrate that CAM blocks effectively the subjective effects of opioid challenges with hydromorphone including limiting drug liking. This study provides clinical proof of concept that CAM will be an effective treatment for opioid use disorder said Behshad Sheldon President and CEO of Braeburn Pharmaceuticals The current opioid crisis demands innovation and CAMs novel technology is now one step closer to providing physicians and patients with a different approach to treating this deadly chronic disease. The primary endpoint was met for both CAM doses demonstrating blockade of the subjective effects of hydromorphone as measured by the Drug Liking Visual Analog Scale. Furthermore CAM was well tolerated across the course of treatment.  The study results show that CAM provides rapid and extended blockade of opioid effects said Fredrik Tiberg President and CEO of Camurus. The results also confirm the dose selection in the current Phase  program and the potential of CAM as a future treatment alternative for patients with opioid use disorder from initiation to longterm maintenance.  The current study demonstrated that weekly injections of CAM produced significant and robust opioid blockade a critical mechanism of efficacy for medications treating opioid dependence. CAM has the potential to alter the current treatment paradigm for opioid dependence said Sharon Walsh Ph.D Professor of Behavioral Science and Director of the Center on Drug and Alcohol Research University of Kentucky Because of its long acting properties CAM may decrease patient and physician burden improve access to treatment and obviate public health concerns about illicit diversion of buprenorphine. We were pleased to be involved in the development of CAM and are hopeful that it will serve as another safe and effective therapeutic option for patients with opioid use disorder. The ability of CAM to produce a longlasting and robust blockade of hydromorphoneinduced Drug Liking is especially encouraging said Sandra D. Comer Ph.D Professor of Neurobiology Columbia University. Importantly the fact that CAM will be given in the clinic by health providers should address concerns about diversion of buprenorphine for illicit use. We feel that this medication with its ease of administration and flexible dosing capabilities could significantly improve management of patients. About the Phase  Trial The Phase  study was a threecenter randomized doubleblind inpatient study to evaluate the degree of subjective opioid blocking efficacy of CAM qw in nontreatmentseeking participants with moderatetosevere opioid use disorder. After screening participants were randomized to different CAM qw onceweekly injections for two weeks. During this period four challenge sessions were conducted with a randomized hydromorphone dose to determine subjective liking score based on a visual analogue scale. Additional information on the design of the trial can be found at  http . About CAM The investigational CAM buprenorphine subcutaneous injection products for treatment of opioid use disorder are being developed as onceweekly and oncemonthly formulations each with multiple doses to cover all phases of treatment from initiation through maintenance. The CAM products are designed for administration by healthcare personnel to ensure proper delivery that minimizes the risks of diversion abuse misuse and accidental exposure. The CAM products have been evaluated in three Phase  clinical trials which evaluated the safety and tolerability as well as pharmacokinetic and pharmacodynamic properties of the products in a total of  individuals opioiddependent patients and healthy volunteers under naltrexone blockage. Four more trials including two Phase  studies are currently ongoing. CAM is also being developed for treatment of chronic pain.  About Braeburn Pharmaceuticals  Braeburn Pharmaceuticals an Apple Tree Partners company is a pillfree pharmaceutical company delivering precision medicine in neuroscience. In September  the Food and Drug Administration FDA accepted for review Braeburns New Drug Application for its lead candidate Probuphine a sixmonth buprenorphine implant for treatment of opioid addiction. The Agency set May   as the target date for action.  Longacting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in these conditions which are often complicated by stigma and present significant public health challenges. Braeburns investigational product pipeline consists of longacting implantable and injectable therapies for serious neurological and psychiatric disorders including opioid addiction pain and schizophrenia. Candidates include Probuphine a sixmonth buprenorphine implant for treatment of opioid addiction CAM weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain a risperidone sixmonth implant for treatment of schizophrenia and a novel molecule ATI for treatment of schizophrenia. More information on Braeburn can be found at  http  About Camurus Camurus is a Swedish researchbased pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with bestinclass potential are conceived based on the proprietary FluidCrystal drug delivery technologies and an extensive RD expertise. Camurus clinical pipeline includes products for treatment of cancer endocrine diseases pain and addiction developed inhouse and in collaboration with international pharmaceutical companies. The companys share is listed on Nasdaq Stockholm under the ticker CAMX. For more information visit  http  Media contacts Fredrik Tiberg President  CEO Tel      fredrik.tibergcamurus.com mailtofredrik.tibergcamurus.com http  Sherry Feldberg MSLGROUP Boston  braeburnpharmamslgroup.com mailtobraeburnpharmamslgroup.com Logo  httpphotos.prnewswire.comprnhLOGO  Logo  httpphotos.prnewswire.comprnhLOGO  SOURCE Braeburn Pharmaceuticals Camurus Related Links http"